《大行報告》高盛:阿里巴巴(09988.HK)擁多個增長引擎 目標價上調至341元
高盛發表研報指,在參與阿里巴巴(09988.HK)投資者日後,發掘到阿里多個增長引擎,對增長前景有信心,將目標價上調至341元,重申評級「確信買入」。
報告指,阿里潛在業務範圍更擴展到房地產、雜貨、快速消費品及醫藥等,預期合計商品成交金總額可達1.36萬億元人民幣,隨著二手商品、直播等變現率不足的業務逐步改善,阿里的整體電商轉換率(take rate)可望提升,預期由2020年的4.3%,提升至2022年的5.1%及2024年的5.5%。
雲業務方面,該行預計其估值為1,980億美元,至2021年度EBITA將可轉正,並至2024年達到約30%利潤率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.